Emmes and Casimir announce research into new home assessment for Duchenne muscular dystrophy BioBuzz

The results of the Duchenne de Casimir video evaluation are presented in a new article


ROCKVILLE, Md., April 27, 2022 /PRNewswire/ — Emmes, a global, full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Casimir’s research on the development of dashboards of Duchenne’s video assessment (DVA) was published in PLOS ONE. Emmes acquired Casimir in March 2022, and the group is now part of Emmes’ Rare Disease Center, Orphan Reach™.

The DVA is a new home-based clinical outcome assessment that measures ease of movement in people with Duchenne muscular dystrophy (DMD) through the identification of compensatory movement patterns. Caregivers video-record patients performing specific movement tasks at home using a secure mobile app. The article describes the development of scorecards that DVA-trained physiotherapists use to score videos.

Casimir research scientist Marielle Contesse was lead author, with Mindy Leffler, co-founder and president, and Christine McSherry, co-founder and chief executive, among other co-authors.

A previous article in Muscle & Nerve, authored by Contesse, Leffler, and other Casimir researchers, presented research findings that demonstrated DVA to be a reliable and valid tool for measuring ease of movement as an indication of severity. disease in patients with DMD. The latest PLOS ONE article details the development of DVA dashboards.

The PLOS ONE article describes research into the development of scorecards conducted with physiotherapists who have extensive experience in assessing patients with DMD. The researchers used a modified two-round Delphi process to gather expert opinion on the dashboards. During the Delphi process, physiotherapists assessed scorecards for the 15 movement tasks. Movement tasks are activities that patients typically do at home, such as walking, climbing stairs, putting on a t-shirt, and eating. After two rounds of review and revision, the expert panel has confirmed that the compensatory movement criteria included in the DVA dashboards are understandable, comprehensive, and clinically meaningful.

“The DVA provides a window into how patients with Duchenne move and function in their home environment,” said Marielle Contesse, “and our dashboards provide a standardized way for physiotherapists to identify movement patterns. The home setting allows us to assess an even wider range of daily movements, and it also eliminates the need for patients and families to travel long distances to clinical trial sites.

She added: “Ultimately, we hope the DVA will be able to detect changes in patient function in a shorter time frame than existing outcome measures. This could potentially reduce the time patients spend participating in a clinical trial.

Emmes Chief Executive Dr Christine Dingivan said: “This research provides the basis for using Casimir’s Duchenne video assessment to expand the possibilities for identifying disease progression and treatment options. treatment. We are also encouraged by the potential use of DVA to assess other muscle and mitochondrial diseases.

About Casimir
Based in Plymouth, Mass., and founded in 2016, Casimir’s CRO services begin with the patient’s perspective as the company embraces new approaches to its clinical studies that help better understand the progression and treatment of rare diseases. It prioritizes virtual trials and remote assessments, focuses on qualitative research centered on the patient experience, and captures the real impact of treatment interventions on patient quality of life through intelligent outcome measures .

About Emmes
Founded in 1977, Emmes is a global, full-service clinical research organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company’s customers include numerous US federal government agencies and institutes and a wide range of biotechnology, pharmaceutical and medical device companies around the world. To learn more about the positive impact of our research on human health, visit the Emmes website at www.emmes.com.

Irene B. Bowles